The British Journal
of Cardiology

This website is intended for healthcare professionals only

New lipid-modifying therapy phase 3 study shows reduced flushing

January 2009 Volume 16, Issue 1 Br J Cardiol 2009;16:16-14

Authors:
BJCardio editorial staff

Phase III clinical study results with a nicotinic acid/laropiprant combination (Tredaptive®), show that in the treatment of patients with dyslipidaemia and primary hypercholesterolaemia, this new lipid-modifying therapy produced less flushing compared with those patients who were treated with extended-release nicotinic acid (Int J Clin Pract 2008;62:1959–70). Treatment with 2 g of the nicotinic acid/laropiprant combination [...]

Phase III clinical study results with a nicotinic acid/laropiprant combination (Tredaptive®), show that in the treatment of patients with dyslipidaemia and primary hypercholesterolaemia, this new lipid-modifying therapy produced less flushing compared with those patients who were treated with extended-release nicotinic acid (Int J Clin Pract 2008;62:1959–70).

Treatment with 2 g of the nicotinic acid/laropiprant combination produced a significant 18% reduction from baseline in low-density lipoprotein cholesterol (LDL-C) and a 26% reduction in triglycerides compared to placebo across weeks 12-24. In addition, patients treated with the combination experienced significantly less flushing compared with those treated with extended-release nicotinic acid (0.2 days/week versus 0.7 days/week respectively).

Some 69% of patients treated with 1 g of the combination reported either no flushing symptoms, or mild flushing symptoms during the first week of treatment, compared to 44% of those who received extended-release nicotinic acid alone. More than twice as many patients on extended release nicotinic acid (22%) discontinued treatment due to flushing compared with those patients taking the combination (10%).

The nicotinic acic/laropiprant combination has recently received EU marketing authorisation.